19:55 , Jul 13, 2018 |  BC Week In Review  |  Company News

Dermatitis, psoriasis candidate passed from GSK to Dermavant

The Dermavant Sciences dermatology subsidiary of Roivant Sciences GmbH (Basel, Switzerland) will shell out £150 million ($200 million) up front to GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) to receive global rights to atopic dermatitis and psoriasis candidate...
18:57 , Jul 13, 2018 |  BC Week In Review  |  Company News

Novartis to spin out Alcon unit

Novartis AG (NYSE:NVS; SIX:NOVN) said it intends to spin out its Alcon eye care business, while retaining the pharma’s ophthalmology pharmaceuticals portfolio. The spinout will include Alcon’s surgical and vision care assets, which yielded $6.7 billion...
18:53 , Jul 13, 2018 |  BC Week In Review  |  Clinical News

FDA panel votes in favor of GSK's malaria candidate

FDA's Antimicrobial Drugs Advisory Committee voted 13-0 that there is substantial evidence of the effectiveness of tafenoquine from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) to prevent relapse of Plasmodium vivax malaria in patients 16 and older, and...
18:31 , Jul 12, 2018 |  BC Extra  |  Company News

GSK hands off dermatitis, psoriasis candidate to Dermavant

The Dermavant Sciences dermatology subsidiary of Roivant Sciences GmbH (Basel, Switzerland) will shell out £150 million ($200 million) up front to GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) to receive global rights to atopic dermatitis and psoriasis candidate...
16:43 , Jul 6, 2018 |  BC Week In Review  |  Clinical News

Neovacs planning Phase III for lupus therapy on mixed Phase IIb data

Neovacs S.A. (Euronext:ALNEV) plans to start Phase III testing of lupus candidate IFNalpha-Kinoid despite reporting mixed data from a Phase IIb trial in the indication. IFNalpha-Kinoid is an immunotherapy against interferon (IFN) alpha. The therapy met...
15:05 , Jul 3, 2018 |  BC Extra  |  Clinical News

Neovacs planning Phase III for lupus therapy on mixed Phase IIb data

Neovacs S.A. (Euronext:ALNEV) plans to start Phase III testing of lupus candidate IFNalpha-Kinoid despite reporting mixed data from a Phase IIb trial in the indication on Tuesday. IFNalpha-Kinoid is an immunotherapy against interferon (IFN) alpha. The...
03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate of...
20:52 , Jun 29, 2018 |  BC Extra  |  Company News

Novartis to spin out Alcon unit

Novartis AG (NYSE:NVS; SIX:NOVN) said it intends to spin out its Alcon eye care business, while retaining the pharma’s ophthalmology pharmaceuticals portfolio. The spinout will include Alcon’s surgical and vision care assets, which yielded $6.7 billion...
18:28 , Jun 29, 2018 |  BC Week In Review  |  Clinical News

FDA panel to discuss GSK’s malaria candidate

FDA's Antimicrobial Drugs Advisory Committee will meet on July 12 to discuss an NDA for single-dose 150 mg tafenoquine from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) to prevent relapse of Plasmodium vivax malaria. Tafenoquine, an 8-aminoquinoline derivative,...
22:31 , Jun 25, 2018 |  BC Extra  |  Company News

FDA panel to discuss GSK’s malaria candidate

FDA's Antimicrobial Drugs Advisory Committee will meet on July 12 to discuss an NDA for single-dose 150 mg tafenoquine from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) to prevent relapse of Plasmodium vivax malaria. Tafenoquine, an 8-aminoquinoline derivative,...